Filing Flows › Comparisons › LMAT vs MDXG
Lemaitre Vascular vs Mimedx Group: LMAT and MDXG compared
Lemaitre Vascular is the larger company: $68.0M of revenue in its latest quarter (Q3 2026) against $62.3M for Mimedx Group (Q3 2026). Lemaitre Vascular is growing faster (+11% against -45% a year earlier). Lemaitre Vascular is more profitable, with an operating margin of 26.0% against -18.8%.
Where the money goes: LMAT and MDXG
Lemaitre Vascular (LMAT) · Q3 2026
Lemaitre Vascular, Q3 2026: revenue $68.0M (+11% year over year), operating margin 26.0%, net earnings $15.0M, operating cash flow $22.0M. The chart follows the revenue to costs, profit and cash.
Mimedx Group (MDXG) · Q3 2026
Mimedx Group, Q3 2026: revenue $62.3M (-45% year over year), operating margin -18.8%, net loss $8.7M, operating cash flow $3.9M. The chart follows the revenue to costs, profit and cash.
| Lemaitre Vascular (LMAT) | Mimedx Group (MDXG) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $68.0M | $62.3M |
| Revenue growth, Y/Y | +11% | -45% |
| Gross margin | 71.7% | — |
| Operating margin | 26.0% | -18.8% |
| Net earnings | $15.0M | −$8.7M |
| Net margin | 22.1% | -13.9% |
| Operating cash flow | $22.0M | $3.9M |
| Free cash flow | $19.7M | $3.8M |
| Market value | $2.0B | $683M |
| P/E | 30.2× | — |
| Analysts’ mean target | $107.00 | $7.00 |
Where the revenue comes from
Mimedx Group
- Surgical: $40.0M (64%)
- Wound: $22.3M (36%)
Questions
Which is bigger, Lemaitre Vascular or Mimedx Group?
Lemaitre Vascular is the larger company: $68.0M of revenue in its latest quarter (Q3 2026) against $62.3M for Mimedx Group (Q3 2026).
Is Lemaitre Vascular or Mimedx Group growing faster?
Lemaitre Vascular is growing faster (+11% against -45% a year earlier).
Which is more profitable, Lemaitre Vascular or Mimedx Group?
Lemaitre Vascular is more profitable, with an operating margin of 26.0% against -18.8%.
More: Lemaitre Vascular earnings · how Lemaitre Vascular makes money · Mimedx Group earnings · how Mimedx Group makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Oct 28, 2026). Fiscal quarters can end on different dates. Not investment advice.